Drug Profile
Research programme: anti-infectives - Altimmune/Panacea Biotec
Alternative Names: Biodefense therapies - Altimmune/Panacea BiotecLatest Information Update: 05 May 2017
Price :
$50
*
At a glance
- Originator Panacea Biotec; PharmAthene
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Infections
Most Recent Events
- 04 May 2017 Altimmune merged with PharmAthene and the combined entity was renamed as Altimmune
- 13 Oct 2008 Early research in Infections in USA (unspecified route)